Total revenues and other operating income of EUR365.4 million for the full year 2010 compared to EUR358.0 million in 2009. Due to write-downs of Quinvaxem® inventory and higher operating expenses, operating loss for the year was EUR34.3 million compared to EUR39.0 million operating profit in 2009. The year ended with a net loss of EUR27.6 million compared to EUR23.9 million net profit in the previous year and undiluted EPS of minus EUR0.34 compared to EUR0.34 in 2009.
↧